Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.

Sylvie RotteyJeffrey ClarkeKyaw AungJean-Pascal MachielsBen MarkmanKimberley M HeinhuisMichael MillwardMartijn Paul LolkemaSandip Pravin PatelPaul de SouzaMatteo Duca Curigliano Giuseppe Armando Santoro Takafumi KoyamaMichelle BrownHeather VezinaChunsheng HeQuincy Siu-Chung Chu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

BMS-986148 ± nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.

Keyphrases

dna damage
study protocol
clinical trial
phase iii
cell cycle
pain management
phase ii
case control
cancer therapy
randomized controlled trial
human health
oxidative stress
risk assessment